Physician profile
Michael A Washinsky
NPI 1801821194
$13,412.91
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,532 · 2020: $2,647 · 2021: $2,606 · 2022: $2,452 · 2023: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,170.06 | 2019-2023 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $2,157.00 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,372.64 | 2019-2023 | Breztri, Farxiga |
| Pfizer INC. | $1,126.22 | 2019-2023 | |
| Lilly USA, LLC | $818.67 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.07 | 2019-2023 | Stiolto Respimat, Synjardy, Jardiance |
| Abbvie INC. | $686.39 | 2020-2023 | Vraylar, Qulipta, Ubrelvy |
| Amarin Pharma, INC. | $616.29 | 2019-2021 | |
| Glaxosmithkline, LLC. | $550.58 | 2019-2023 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $527.51 | 2022-2023 | |
| Astellas Pharma US INC | $441.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $405.78 | 2019-2022 | |
| Abbott Laboratories | $362.66 | 2021-2023 | Freestyle Libre 2, Infinity, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $323.13 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.78 | 2019-2023 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $147.80 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $131.91 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $107.58 | 2019-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $90.77 | 2019-2022 | |
| Radius Health, INC. | $79.87 | 2019-2021 | |
| Mylan Specialty L.P. | $46.02 | 2019 | |
| Sanofi Pasteur INC. | $44.67 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $42.27 | 2023 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $25.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $23.80 | 2019 | |
| Boston Scientific Corporation | $21.50 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.50 | 2022 | |
| Eisai INC. | $19.71 | 2020 | |
| Phadia US INC. | $19.13 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.98 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.63 | 2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $12.20 | 2019 | |
| Medtronic, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Washinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.